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1. Introduction 
Self-monitoring blood glucose (SMBG) is an important component of modern therapy for 
diabetes mellitus. SMBG has been recommended for people with diabetes and their health 
care professionals in order to achieve a specific level of glycaemic control and to prevent 
hypoglycaemia. The goal of SMBG is to collect detailed information about blood glucose 
levels at many time points to enable maintenance of a more constant glucose level by more 
precise regimens. It can be used to aid in the adjustment of a therapeutic regimen in 
response to blood glucose values and to help individuals adjust their dietary intake, 
physical activity, and insulin doses to improve glycaemic control on a day-to-day basis. 
SMBG can aid in diabetes control by: (http://www.diabetes.co.uk/blood-glucose/blood-
glucose-self-monitoring.html) 
 facilitating the development of an individualized blood glucose profile, which can then 
guide health care professionals in treatment planning for an individualized diabetic 
regimen; 
 giving people with diabetes and their families the ability to make appropriate day-to-
day treatment choices in diet and physical activity as well as in insulin or other agents; 
 improving patients’ recognition of hypoglycaemia or severe hyperglycaemia;  
 enhancing patient education and patient empowerment regarding the effects of lifestyle 
and pharmaceutical intervention on glycaemic control. 
 helps to determine which foods or diet are best for one’s control 
 helps inform the patient and doctor about how well the medication regime is working  
 reduces anxiety about, and increases understanding of, hypoglycaemia. This is because 
if untreated hypoglycaemia can result in coma for diabetic patients and is therefore a 
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condition that diabetics try to avoid through proper action. To this end, regular testing 
can predict dangerous drop in blood glucose concentration which can lead to 
hypoglycaemia.  
 is important for undertaking dangerous tasks which could be influenced by high or low 
blood sugar, such as driving and handling dangerous machinery 
Disadvantages are mainly seen when either the patient lacks motivation to test or does not 
have sufficient education on how to interpret the results to make sufficient use of home 
testing equipment. Where this is the case, the following disadvantages may outweigh the 
potential benefits: 
 anxiety about one’s blood sugar control and state of health 
 the physical pain of finger pricking 
 expense to the NHS or other medical body 
Numerous trials have been carried out to determine the true impact of SMBG on glycaemic 
control. Some, including randomized, controlled trials, have demonstrated the efficacy of 
SMBG. Among patients with type 1 diabetes, SMBG has been associated with improved 
health outcomes. [1] Specifically, increasing frequency of SMBG was linearly correlated with 
reductions in HbA1c among type 1 patients in Scotland. [2] Among patients with type 2 
diabetes, a higher frequency of SMBG was associated with better glycaemic control among 
insulin-treated patients who were able to adjust their regimen. [3]  
SMBG works by having patients perform a number of glucose tests each day or each week. 
The test most commonly involves pricking a finger with a lancet device to obtain a small 
blood sample, applying a drop of blood onto a reagent strip (typically an enzyme electrode), 
and determining the glucose concentration by inserting the strip into an electronic meter for 
an automated reading. Test results (a measure of the glucose concentration in the blood 
sample) are then recorded either in a logbook or stored in the glucose meter’s electronic 
memory. People with diabetes can be taught to use their SMBG results to correct any 
deviations out of a desired target range by changing their carbohydrate intake, exercising, or 
using more or less insulin. 
The frequency with which patients with diabetes should monitor their blood glucose level 
varies from person to person. Most experts agree that insulin-treated patients should monitor 
blood glucose at least four times a day, most commonly fasting, before meals, and before bed. 
In addition, patients using insulin can benefit by obtaining postprandial blood glucose 
readings to help them more accurately adjust their insulin regimen. A positive correlation 
between frequency of SMBG and glycaemic control among patients with insulin-treated type 
1 or type 2 diabetes has been demonstrated. [1-3] Patients treated with intermediate, short-
acting, or rapid-acting insulin may benefit from SMBG data to make adjustments in their 
regimen. 
For patients with type 2 diabetes, optimal SMBG frequency varies depending on the 
pharmaceutical regimen and whether patients are in an adjustment phase or at their target 
for glycaemic control. If a patient is on a stable oral regimen with HbA1c concentration 
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within the target range, infrequent SMBG monitoring is appropriate. In such cases, patients 
can use SMBG data as biofeedback at times of increased stress or changes in diet or physical 
activity. [4, 5]  
It is important to point out however that this debate is not straightforward, however. One 
factor that is often overlooked is that the numbers obtained by testing are only one part of 
the picture, which requires additional data to be complete. For example, it is important to 
relate the number to what and when the patient last ate. The patient’s exercise regime must 
also be considered, as well as when and how much medication has been taken. If this were 
not complicated enough, the patient (and physician) need to consider factors such as 
whether the patient has recently been ill, or even subjected to high levels of stress, which can 
distort the picture. 
Blood glucose meters which utilise an enzyme electrode (a term first coined by Updike and 
Hicks in the late sixties [6]) as the glucose sensing element are particularly suitable medical 
devices for SMBG. 
All the commercial electrochemical meter systems typically comprise two components. The 
meter - applies potential differences in a programmed sequence to the sensor, collects 
current data and analyses the current time response of the sensor, records and displays 
results. The enzyme electrode (or biosensor) test strip - collects the blood sample, the sample 
undergoes an enzymatic chemical reaction followed by an electrochemical detection step. 
The patient simply inserts the enzyme electrode into the meter and applies a small drop of 
blood to the sensor. After a short delay (typically 5 seconds) the blood glucose value is 
displayed by the meter in mg/dL or mmol/L. 
The advantages offered by biosensors in SMBG arise for the following reasons. Blood is a 
complex fluid and glucose levels vary widely over time in a single patient, many factors 
besides glucose vary in blood from healthy, patients (haematocrit, oxygen levels, and 
metabolic by-products) therefore great specificity is a prime requirement. In addition, 
patients with diabetes may have a wide range of other medical problems creating even 
greater variation in their blood. Finally, biosensors can be used directly in the blood without 
requiring major modifications to the biological sample (increased temperature or pressure, 
dramatic pH changes, addition of highly reactive chemicals, etc).  
The enzyme electrodes commonly used in SMBG can be defined as a combination of any 
electrochemical probe with a thin layer of enzyme based reagent that is selective for glucose 
(or other important analytes such as β-hydroxybutyrate). In these devices, the function of the 
enzyme is to provide selectivity by virtue of its biological affinity for a particular substrate 
molecule. For example, an enzyme is capable of catalysing a particular reaction of a given 
substrate even though other isomers of that substrate or similar substrates may be present.  
Typically, the progress of the enzyme reaction (which is related to the concentration of 
analyte) is monitored by the rate of formation of product or the disappearance of a reactant. 
If either the product or reactant is electroactive, then the progress of the reaction can be 
monitored directly using amperometry. In this technique, current flow is measured in 
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response to an applied voltage. The resultant current is monitored by the meter and then 
interpolated into an accurate measurement of glucose using on-board software algorithms 
giving the user a concentration value in typically less than 7 seconds. 
The final method of analysis used will ultimately depend on several properties of the 
enzyme. The main considerations are; 
1. does the enzyme contain redox active groups 
2. are the products of the biochemical reaction electroactive 
3. is one of the substrates or cofactors electroactive 
4. what is the required speed of response 
5. what will be the final application of the sensor 
The answer to the first three criteria will depend largely on the system under investigation. 
The answer to the latter three depends on the requirements and application of the sensor 
under consideration. If the enzyme does not contain any redox groups, then the method of 
analysis will be restricted to monitoring either the release of products or the consumption of 
substrate by their reaction at the transducing electrode. The current produced can then be 
related to the concentration of analyte. Of particular relevance to this article, are the devices 
that incorporate nicotinamide adenine dinucleotide (NAD), flavin adenine dinucleotide (FAD) 
or pyrroloquinoline quinone (PQQ) dependent dehydrogenase enzymes. 
2. Electrochemical oxidation of NAD(P)H 
Given that the nicotinamide coenzymes are electron carriers, and therefore by definition 
electroactive, it would appear at first sight (points 2 and 3 above) that these systems would 
be ideal candidates for commercial enzyme electrode devices. The electrochemical oxidation 
of NADH to NAD+ is however both chemically and kinetically complicated at common 
electrode surfaces such as gold, platinum or glassy carbon. 
The electrochemical detection of NADH has generated great interest because the pyridine 
nucleotides NAD+ and NADP+ are ubiquitous in all living systems and are required for the 
reactions of more than 450 oxidoreductases. [7] Although the formal potential of NADH/ NAD+ 
couple in neutral pH at 25 C is estimated to be 0.56 vs. SCE [8, 9] significant over-potential is 
often required for the direct oxidation of NADH at bare electrodes. [10] Unlike in nature where 
the oxidation of NADH occurs as a 1-step hydride transfer, on bare electrodes the reaction has 
been shown to occur via a different and higher energy pathway which produces biologically 
inactive NAD. radicals as intermediates. The large amount of energy required to produce these 
intermediates is the origin of the large overpotential (typically 1 Volt) required at bare 
electrodes. As a result, the direct electrochemical oxidation of NADH has been shown to 
produce a mixture of products including biologically active NAD+, (NAD)2 dimers and 
products from the side reactions of the electrogenerated NAD. radicals.  
In addition, the direct oxidation of NADH is often accompanied by electrode fouling due to 
the polymerisation oxidation products on the electrode surface. [11] The fouling of the electrode 
surface can occur by two mechanisms. First, the NAD. radicals interact directly with oxide 
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functionalities on the surface of the electrode and second the reaction product, NAD+, adsorbs 
onto the electrode surface. Both of these processes are irreversible and result in the gradual 
blocking of the electrode during continued oxidation. It is this electrode fouling that results in 
the irreproducibility of the analytical signal from bare electrodes. In addition, if this method 
were to be used in commercial glucose sensors for SMBG, the high over potentials required 
would result in the response being a combination of signals from the oxidation of both NADH 
and common interferents, e.g. ascorbic acid, uric acid, paracetamol etc. found in blood. 
The problems mentioned above can be overcome by using small catalytic molecules called 
mediators. These molecules can transfer charge from the reduced coenzyme directly to the 
electrode thereby bypassing the direct oxidation of NADH. The use of this approach has three 
potential advantages when compared to the direct oxidation of the reduced nicotinamide. First, 
by judicious choice of the mediator problems associated with electrode fouling or competing 
reactions can be avoided (especially true if he chosen mediator has a site for hydride transfer). 
Virtually 100% of the oxidation product via this mechanism is biologically active NAD. Second, 
the rate of electron transfer between the NADH molecule and the mediator can be enhanced 
resulting in a more stable increased signal. The rate at which NADH is chemically oxidised will 
governed to a large extent by the potential difference between the formal redox potential of the 
two species. Finally, a mediator can be selected with a redox potential that will limit the effects 
of interference. This is particularly relevant in cases where the bio-analyte is present in blood at 
low concentrations as in the case of beta-hydroxybutyrate (0.0 – 0.3mEq/L). The electrocatalytic 
oxidation of NADH at a modified electrode is shown schematically in Figure 1. Of particular  
 
Figure 1. Cyclic voltammograms of the o-AP modified GC electrode in phosphate buffer (a) in the 
absence and in the presence of increasing concentrations of NADH/mM: (b) 0.1, (c) 0.3 and (d) 0.5; and 
(e) 0.6 at bare GC in phosphate buffer (0.1 M, pH 7.0). Scan rate = 10 mV/s. Note, the peak oxidation for 
NADH at the bare electrode occurs at 0.6 Volts. When the electrode is modified, in this case with o-
amino phenol the oxidation of NADH is concomitant with the oxidation of the immobilised redox 
couple (traces b – d). Figure and data adapted from reference 11. 
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interest are voltammograms a and e. These show the direct oxidation of NADH (e) at the glassy 
carbon electrode and the cyclic voltammogram (a) of the immobilised species. Addition of 
NADH to the solution causes an increase in 1. Note that the signal due to the oxidation of 
NADH now occurs at the potential of the mediator resulting in a decrease in the operating 
voltage of approximately 0.3 V. 
Among the mediators used so far are quinones, diimines, ferrocene, thionine oxometalates, 
polymetallophthalocyanines, ruthenium complexes, pyrroloquinoline quinone, fluorenones, 
and quinonoid redox dyes such as indamines, phenazines, phenoxazines and 
phenothiazines.11 A generalised reaction schematic for the mediated oxidation of NADH is 
shown below in Figure 2.  
 
Figure 2. Scheme showing the mediated oxidation of NADH. In this context, the mediator reacts with 
NADH in a chemical step to oxidise it (a) and is itself reduced. The mediator is then itself reoxidised at 
the electrode surface (step b). The chemical oxidation of NADH by this mechanism bypasses the 
problems associated with the direct oxidation at a bare electrode surface.  
To design an NADH sensor, the mediator is normally immobilized on the electrode surface 
or within the electrode material. Mediators can be immobilized by chemisorption by 
covalent attachment directly electrode surface or by electrochemical polymerisation of the 
mediators at the electrode surface or, alternatively via covalently attached/physically 
entrapment in polymers, incorporation in carbon paste grown at electrode surface or 
deposited on the electrodes by drop coating. The method that is ultimately chosen to 
produce the modified electrode depends upon the method of mass production (for 
commercial sensors) and the materials used in the device. For example, in sensors that 
utilise screen printed carbon based electrodes (screen-printing technology is a kind of low-cost 
thick film technology which allows to deposit thick films, a few to hundreds micrometers and is well 
suited for mass production and portable devices. Such a micro fabrication route offers high-volume 
production of extremely inexpensive and yet highly reproducible disposable enzyme electrodes – this 
will be discussed further in the text) it is convenient to incorporate the mediator directly into 
the carbon ink particularly if the mediator contains delocalised aromatic rings, as found in 
quinine and phenoxazine dye based mediators, which form strong chemisorbed bonds with 
the carbon and graphite plates. The mediator loading, activity stability etc can all be 
investigated using conventional electrochemical techniques such as DC cyclic voltammetry. 
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It is important that modified electrodes designed for the reoxidation of NADH are stable 
over their stated shelf-life, respond only to NADH and not to any other species present in 
the blood sample satisfy the following kinetic requirements; i) the reaction between the 
NADH molecule and the mediator is fast, ii) the transfer of charge within the mediating 
layer is fast and iii) the electron transfer between the reduced mediator and the electrode is 
also fast. 
3. Kinetic modelling of NADH oxidation at chemically modified 
electrodes. 
In the scientific literature, NADH oxidation at chemically modified electrodes is most 
commonly suggested to occur via a two-step reaction mechanism. In the first step, NADH 
forms a charge transfer complex with the oxidised form of the mediator bound to the electrode 
surface. In the second step, electron exchange takes lace and the complex breaks down 
producing NAD+ and a reduced mediator site. Because the electrode is polarised, the reduced 
mediator site is reoxidised in a non-rate limiting electron exchange to the bulk electrode 
material. This scheme is shown in Figure 3. The important kinetic constants are also 
represented.  
 
Figure 3. Two-step mechanism commonly proposed for the oxidation of NADH at chemically modified 
electrodes. The mediator and NADH form a charge transfer complex that dissociates to give rise to the 
reduced mediator and biologically active NAD+.  
For this type of mechanism, the catalytically limiting current (ik) observed under controlled 
hydrodynamic conditions can be expressed as: ik = nFAKcatCNADH/KM where CNADH is the 
bulk concentration of NADH and  represents the concentration of binding sites in the 
immobilised film. This type of model assumes that the rate of electron transfer between the 
mediating species in the film and the NADH is sufficiently fast so as not to be rate limiting, 
the NADH freely diffuses into the film whereupon it adsorbs to the catalytic site and it 
undergoes oxidation to NAD+. Also, the expression for ik is valid only for thin films where 
the concentration of NADH is insufficient to saturate the binding sites.[12] 
Due to the formation of the charge-transfer complex, this reaction scheme is commonly 
analysed using Michaelis-Menten kinetics. From figure 3 it is possible to construct the 
following kinetic argument. 
This is now a straight line plot. From the slope of such a plot, values of k+2 can be calculated. 
By extrapolation of zero NADH concentration, i.e. the intercept, values of KM can be 
estimated. Values for kObs can be obtained from Koutecky-Levitch plots under steady state  
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Scheme 1.  
oxidation conditions as described by Compton and Hancock.[12] Typically, values of kObs 
tend to be in the range 10-3 to 10-1 cm s-1. Thus it is possible using such laboratory techniques 
to ensure that the surface coverage of mediator (moles/cm2) is optimised to achieve 
favourable measurement linearity and speed of response. 
4. Commercial sensors for SMBG incorporating NAD(P)-linked 
dehydrogenase enzymes 
Commercial examples of this type of device are the “Abbott Optium Xceed glucose and -
ketone test strips” (http://www.abbottdiabetescare.com/precision-xtra-blood-glucose-and-
ketone-monitoring-system.html). These strips make use of the NAD+ dependent glucose 
dehydrogenase (EC 1.1.1.47) and NAD+ dependent -hydroxybutyrate dehydrogenase (EC 
1.1.1.30). Exogenous NAD+ is incorporated into the reagent ink which is deposited onto the 
individual electrode by screen printing. The mediator molecule that is used to recycle the 
reduced form of the coenzyme is phenanthroline quinone (Manufacturers own vial insert data 
sheet). Advantages often cited with this type of chemistry include good selectivity and no 
reaction with oxygen. 
5. Screen printing as a means of mass-manufacturing enzyme sensors 
Screen printing is arguably the most versatile of all printing processes. It can be used to print 
on a wide variety of substrates, including paper, paperboard, plastics, glass, metals, fabrics, 
and many other materials including paper, plastics, glass, metals, nylon and cotton. Some 
common products from the screen printing industry include posters, labels, decals, signs, and 
all types of textiles and electronic circuit boards. The advantage of screen printing over other 
print processes is that the press can print on substrates of any shape, thickness and size. 
A significant characteristic of screen printing is that a greater thickness of the ink can be 
applied to the substrate than is possible with other printing techniques. This allows for some 
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very interesting effects that are not possible using other printing methods. Because of the 
simplicity of the application process, a wider range of inks and dyes are available for use in 
screen printing than for use in any other printing process. The major chemicals used include 
screen emulsions, inks, and solvents, surfactants, caustics and oxidizers used in screen 
reclamation.  
Screen printing consists of three elements: the screen which is the image carrier; the 
squeegee; and ink. The screen printing process uses a porous mesh stretched tightly over a 
frame made of wood or metal. Proper tension is essential to accurate colour registration. The 
mesh is made of porous fabric or stainless steel mesh. A stencil is produced on the screen 
either manually or photochemically. The stencil defines the image to be printed in other 
printing technologies this would be referred to as the image plate. 
 Screen printing ink is applied to the substrate by placing the screen over the material. Ink 
with a paint-like consistency is placed onto the top of the screen. Ink is then forced through 
the fine mesh openings using a squeegee that is drawn across the screen, applying pressure 
thereby forcing the ink through the open areas of the screen. Ink will pass through only in 
areas where no stencil is applied, thus forming an image on the printing substrate. The 
diameter of the threads and the thread count of the mesh will determine how much ink is 
deposited onto the substrates. Figure 4 shows an example of an image for an electrochemical 
cell consisting of a working, a counter and a reference element. This type of structure can be 
easily produced by screen printing. 
 
Figure 4. Example of a screen printed electrochemical cell (screen image) showing the Reference element 
(A), the working electrode (B) and the counter electrode (C). Comercially available screen printed 
electrodes for research purposes can be obtained from DropSens, Edificio CEEI - Parque Tecnológico de 
Asturias - 33428 Llanera (Asturias) Spain. http://www.dropsens.com/en/screen_printed_electrodes_pag.html 
Many factors such as composition, size and form, angle, pressure, and speed of the blade 
(squeegee) determine the quality of the impression made by the squeegee. At one time most 
blades were made from rubber which, however, is prone to wear and edge nicks and has a 
tendency to warp and distort. While blades continue to be made from rubbers such as 
neoprene, most are now made from polyurethane which can produce as many as 25,000 
impressions without significant degradation of the image. 
If the item was printed on a manual or automatic screen press the printed product will be 
placed on a conveyor belt which carries the item into the drying oven or through the UV 
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curing system. Rotary screen presses feed the material through the drying or curing system 
automatically. Air drying of certain inks, though rare in the industry, is still sometimes 
utilized. 
The rate of screen printing production was once dictated by the drying rate of the screen 
print inks. Due to improvements and innovations the production rate has greatly increased. 
Some specific innovations which affected the production rate and have also increased screen 
press popularity include: 
 Development of automatic presses versus hand operated presses which have 
comparatively slow production times.  
 Improved drying systems which significantly improves production rate.  
 Development and improvement of U.V. curable ink technologies  
 Development of the rotary screen press which allows continuous operation of the press. 
This is one of the more recent technology developments.  
There are three types of screen printing presses. The flat-bed (probably the most widely 
used), cylinder, and rotary. Flat-bed and cylinder presses are similar in that both use a flat 
screen and a three step reciprocating process to perform the printing operation. The screen 
is first moved into position over the substrate, the squeegee is then pressed against the mesh 
and drawn over the image area, and then the screen is lifted away from the substrate to 
complete the process. With a flat-bed press the substrate to be printed is positioned on a 
horizontal print bed that is parallel to the screen. Rotary screen presses are designed for 
continuous, high speed web printing. The screens used on rotary screen presses are 
seamless thin metal cylinders. The open-ended cylinders are capped at both ends and fitted 
into blocks at the side of the press. During printing, ink is pumped into one end of the 
cylinder so that a fresh supply is constantly maintained. The squeegee is a free floating steel 
bar inside the cylinder and squeegee pressure is maintained and adjusted by magnets 
mounted under the press bed.  
Screen printing inks are moderately viscous inks which exhibit different properties when 
compared to other printing inks such as offset, gravure and flexographic inks though they 
have similar basic compositions (pigments, solvent carrier, toners, and emulsifiers). There 
are five different types of screen ink to include solvent, water, and solvent plastisol, water 
plastisol, and UV curable.  
5.1. UV curable inks 
UV curable inks consist of liquid pre-polymers, monomers, and initiators which upon 
being exposed to large doses of U.V. Radiation instantly polymerize the vehicle to a dry, 
tough thermosetting resin. They also require less energy, overall, to dry or "cure" compared 
to gas or electric driers. The down side of UV inks is they can cost as much as three times 
that of regular inks and must be handled differently than conventional inks due to safety 
issues. Additionally, solvents are required for clean-up which results in some VOC 
emissions. 
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5.2. Plastisol Inks 
Plastisol inks (both solvent and water based) are used in textile screen printing. Plastisol ink 
is a PVC (polyvinyl chloride) based system that essentially contains no solvent at all. Along 
with UV ink used in graphic screen printing, it is referred to as a 100% solid ink system. 
Plastisol is a thermoplastic ink in that it is necessary to heat the printed ink film to a 
temperature high enough to cause the molecules of PVC resin and plasticizer to cross-link 
and thereby solidify, or cure. The temperature at which most plastisol for textile printing 
cures at is in the range of 149 °C to 166 °C (300 °F to 330 °F). Plastisol inks are commonly 
used for printing graphics on articles such as tee shirts. 
5.3. Solvent inks & water inks 
Solvent and water based screen printing inks are formulated with primarily solvent or 
water. The solvent evaporates and results in VOC emissions. Water based inks, though they 
contain significantly less, may still emit VOC's from small amounts of solvent and other 
additives blended into the ink. The liquid waste material may also be considered hazardous 
waste. Water-based inks are a good choice when a “soft hand” is desirable. Water-based 
inks also have the advantage of being an excellent ink system for high speed roll-to-roll 
yardage printing. Such printing is done on large sophisticated equipment that has very large 
drying (curing) capacity. Finally, because of the fragility of the components used in the 
manufacture of enzyme electrodes, e.g. enzymes, co-enzymes and mediators water based 
inks tend to be the ink of choice when formulating the reagent ink component of the device. 
Screen (or image transfer) preparation includes a number of steps. First the customer 
provides the screen printer with objects, photographs, text, ideas, or concepts of what they 
wish to have printed. The printer must then transfer a "picture" of the artwork (also called 
"copy") to be printed into an "image" (a picture on film) which can then be processed and 
eventually used to prepare the screen stencil. Once the artwork is transferred to a positive 
image that will be chemically processed onto the screen fabric (applying the emulsion or 
stencil) and eventually mounted onto a screen frame that is then attached to the printing 
press and production begins. Screen mesh refers to the number of threads per inch of fabric. 
The more numerous the threads per inch the finer is the screen. Finer mesh will deposit a 
thinner ink deposit. This is a desirable affect when printing a very fine detail and halftones. 
Typically a fabric should be 200-260 threads per inch. Water based inks work best on finer 
mesh. These are generally used in graphic and industrial printing. Course mesh will deposit 
a heavier ink deposit. This type of screen is used on flatter, open shapes. Typically a course 
screen mesh will be 160-180 threads per inch. These are generally used in textile printing. An 
example artwork for a multi-layered screen printed device. Each colour represents a 
different layer requiring different screens and artworks. 
Enzyme electrodes are normally built up in layers using different art works and different 
inks. The inks range from; conducting carbon and silver inks (to generate the conducting 
pathways and/or the reference half cell of the device), inks containing the various chemical 
and biochemical components of the device (enzyme, buffer salts, mediator, stabilisers etc) 
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and inks that are used to define structural components of the device (insulating inks to 
define the electrode areas and geometries, adhesive inks to provide three dimensional 
elements such as capillary spacers and coloured inks to provide branding and product 
identification.) Each of these individual layers normally requires a separate screen and is 
carried out at a separate printer/dryer station.  
The blood monitors (the systems that the user receives) are made up of three main parts: the 
Optium meter, the Optium Plus blood glucose electrodes, and the Optium blood ß-Ketone 
electrodes. When the blood sample is applied to the electrode, the glucose or ketone (ß-
hydroxybutyrate) in the blood reacts with the chemicals on the electrode. This reaction 
produces a small electrical current that is measured and the result is displayed by the 
sensor. Optium Xceed monitors are designed for testing blood obtained from a finger prick, 
but you can also use it to test blood from other, less painful, sites such as the base of the 
thumb, forearm or upper arm. A recent study published in Clinical Chemistry and Laboratory 
Medicine [13] concluded that the Optium Blood glucose test strip had a within-run 
imprecision coefficient of variation (CV) of 4.2%. Good response linearity was found in 
glucose concentrations in the range 31–444 mg/dL (1.7–24.7 mmol/L). In the concentration 
range studied, the glucose meter error was 5.14% and the linear regression equation was y = 
0.91x +6.2 (r=0.984) against a Modular P clinical analyzer. The Passing-Bablok agreement test 
indicated good concordance of results. However, for glucose concentrations <100 mg/dL (5.6 
mmol/L) (n=69) the error was 6.82% with regression equation y=0.86x+5.9 (r=0.757). 
Between-lot differences amounted to 0.7%–18.2%. The authors concluded that meter had 
good precision and accuracy when compared to the laboratory method and met the quality 
recommendations of the National Committee of Clinical Laboratory Standards (NCCLS, 
currently the Clinical Laboratory Standards Institute), the National Academy of Clinical 
Biochemistry (NACB) and the International Organization for Standardization (ISO). 
6. Ketone sensors which incorporate a NAD-linked dehydrogenase 
In addition to glucose, another important analyte which is of particular relevance to diabetic 
patients is the ketone body, -hydroxybutyrate. Diabetic ketoacidosis (DKA), a condition 
were the level of ketone bodies in the blood are elevated, is a problem that occurs in people 
with diabetes. It occurs when the body cannot use sugar (glucose) as a fuel source because 
there is no insulin or not enough insulin. Fat is used for fuel instead. People with type 1 
diabetes do not have enough insulin, a hormone the body uses to break down sugar 
(glucose) in the blood for energy. When glucose is not available, fat is broken down instead. 
As fats are broken down, acids called ketones build up in the blood and urine. In high levels, 
ketones are poisonous. This condition is known as ketoacidosis. Blood glucose levels rise 
(usually higher than 300 mg/dL) because the liver makes glucose to try to combat the 
problem. However the cells cannot pull in that glucose without insulin. Diabetic ketoacidosis 
is often the first sign of type 1 diabetes in people who do not yet have other symptoms. It can 
also occur in someone who has already been diagnosed with type 1 diabetes. Infection, 
injury, a serious illness, or surgery can lead to diabetic ketoacidosis in people with type 1 
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diabetes. Missing doses of insulin can also lead to ketoacidosis in people with diabetes. 
People with type 2 diabetes can develop ketoacidosis, but it is rare. It is usually triggered by a 
severe illness. In ketoacidosis, the body fails to adequately regulate ketone production 
causing such a severe accumulation of keto acids that the pH of the blood is substantially 
decreased. In extreme cases ketoacidosis can be fatal. 14 Despite considerable advances in 
diabetes therapy, key epidemiological figures related to DKA remained nearly unchanged 
during the last decades at a global level. Prevention of DKA – especially in sick day 
management – relies on intensive self-monitoring of blood glucose and subsequent, 
appropriate therapy adjustments. Self-monitoring of ketone bodies during hyperglycemia 
can provide important, complementary information on the metabolic state. Both methods for 
self-monitoring of ketone bodies at home are clinically reliable and there is no published 
evidence favouring one method with respect to DKA prevention. 
Ketone sensitive test strips can be manufactured using NAD-linked enzyme, -hydroxybutyrate 
dehydrogenase and chemically modified electrodes like the ones described above. It is 
interesting to note however that in the case of this particular enzyme representatives of the 
common classes of quinoid NADH redox mediator, including Meldola Blue, 4-methyl-1,2-
benzoquinone, 1-methoxy phenazine methosulphate and 2,6-dichloroindophenol, were shown 
to inhibit the NAD-dependent enzyme -hydroxybutyrate dehydrogenase, severely limiting 
their utility in the construction of a stable biosensor electrode for the ketone body -
hydroxybutyrate. [14] The authors speculated that this was due to 1,4-nucleophilic addition 
with enzyme amino acid residues such as cystine present on the enzyme. Consequently, this 
mode of inhibition is overcome through the use of mediators such as 1, 10-phenanthroline 
quinone (Figure 5.)  
 
Figure 5. Chemical structure of 1,10 Phenanthroline quinone (oxidised form). The oxidation potential of 
this molecule is 0.1 Volt vs Ag/AgCl. The electrochemical reduction of 1,10-phenanthroline-5,6-quinone, 
like other quinones, is reversible and occurs by 2e- transfer in a single step in aqueous solution and by 
two 1 e-transfer steps in aprotic media. 
This technology resulted in the launch of the MediSense® Optium™ β-Ketone electrode. 
The strip was stable, (≤10% loss in response at 30 C versus 4 C) with a long shelf life of 18 
months. Diabetics were able to determine their -hydroxybutyrate level with good 
precision (0.43 mM 3-OHB, 10.5% CV; 1.08 mM, 5.9%; 3.55 mM, 3.2%; n = 20 per level) and 
accuracy (versus reference assay: slope = 0.98; intercept = 0.02 mM, r = 0.97, n = 120) over the 
range 0.0–6.0 mM in 30 s using a small volume of blood (5 μl). The electrode had a low 
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operating potential (+200 mV versus Ag/AgCl) such that the effect of electroactive agents in 
blood was minimised. [15-18] 
7. Alternative approaches to ketone sensing using Diaphorase 
The diaphorases (EC1.6.99.3) are a ubiquitous class of flavin-bound enzymes that catalyze the 
reduction of various dyes which act as hydrogen acceptors from the reduced form of di- and 
tri- phosphopyridine nucleotides, i.e. NADH, NADPH. They catalyse the following reaction: 
NADPH  H  acceptor NADP  reduced acceptor      
Either NADH or NADPH may be used as reductants. However, no exchange of 
hydrogen between the coenzymes is catalysed. Typical acceptor molecules include dyes 
such as 2, 6- dichlorophenolindophenol and tetrazolium dyes and redox couples such as 
ferricyanide anions and ferricinium cations. The Expasy entry for diaphorase is 
http://enzyme.expasy.org/EC/1.6.99.3 
 
Figure 6. Calibration curve (B) for the diaphorase based ketone sensor developed and manufactured in 
house (unpublished results). The calibration characteristics are shown over the physiologically relevant 
range 0 – 2.5 mmol/L -hydroxybutyrate spiked into a whole blood sample. Each concentration 
determination is 16 repetitions. The reaction scheme for the sensor is shown in (A). Here, the mediator 
is the ferricyanide anion. HBA in the blood was measured using the Randox RX Monza Chemistry 
Analyser, http://www.randox.com/rx%20monza.php. The test time was 7 seconds. 
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In this configuration, NAD+, Diaphorase, acceptor molecule and -hydroxybutyrate 
dehydrogenase are all formulated together in the enzyme ink and laid down on the test strip 
using an appropriate manufacturing method. Data generated in-house (unpublished results) 
using this kind of prototype test strip (with ferricyanide as the acceptor) is shown below for 
the clinically relevant concentration range of -hydroxybutyrate. The strip was 
manufactured by screen printing (cf above). Ferricyanide, buffer salts, NAD+, binders, 
diaphorase and -hydroxybutyrate dehydrogenase were mixed into a suitable enzyme ink 
and printed onto carbon electrodes. The operating voltage was 0.4 Volts. 
8. Glucose test strips using PQQ linked and FAD-linked glucose 
dehydrogenase 
PQQ-GDH (pyrrolo quinoline quinone glucose dehydrogenase) belongs to a class of 
enzymes called quinoproteins which require ortho-quinone cofactors to oxidize a wide 
variety of alcohols and amines to their corresponding aldehydes and ketones. The soluble 
quinoprotein Glucose Dehydrogenase, EC 1.1.99.17, (sGDH), systematic name D-glucose: 
(pyrrolo-quinoline-quinone)1-oxidoreductase, uses pyrrolo-quinoline quinone (PQQ) as a 
cofactor. sGDH is a strongly basic (pI = 9.5) dimeric enzyme of identical subunits. One 
monomer (50 kDa, 454 residues) has been reported to bind one PQQ molecule and two 
Ca(II) ions. One of the Ca(II) ions is required for activation of the cofactor; the other is 
needed for functional dimerisation of the protein. sGDH oxidizes a wide range of mono-and 
disaccharides and is able to donate electrons to several neutral or cationic artificial electron 
acceptors, including short artificial ubiquinone homologues. The natural electron acceptor of 
PQQ-GDH is ubiquinone although the enzyme will react with a variety of artificial 
acceptors such as the ferricyanide anion ion and the ferricinum cation. The oxidised form of 
PQQ can be converted into the reduced form PQQH2 by the transfer of 2 electrons and two 
protons from the substrate molecule. [19-21]  
There are two types of PQQ-GDH enzymes that can be considered for biosensor design. One 
is intracellular and soluble (sPQQ-GDH) whereas the other molecule is insoluble and firmly 
bound to the outer surface of the cytoplasmic membrane (mPQQ-GDH). mPQQ-GDH is 
very selective for glucose but has the disadvantage that it requires extensive solubilisation 
and stabilisation with detergent molecules[22] . For these reasons, mPQQ-GDH has not been 
successfully commercialised for biosensor application. It can oxidise a number of 
monosaccharides, in addition to glucose, such as maltose, mannose and lactose. 
Consequently, patients that have high levels of, for example maltose in the blood (which 
could result as a side effect of peritoneal dialysis) or have an inbred genetic disorder 
resulting in impaired carbohydrate metabolism, would obtain an inaccurate high reading 
when testing with glucose electrodes incorporating this enzyme. The increasing demand for 
dialysis and slower growth in capacity for haemodialysis has reinforced the need for an 
integrated approach to providing dialysis. Peritoneal dialysis is the preferred option for a 
proportion of patients with end stage renal failure. Peritoneal dialysis fluid usually contains 
glucose as an osmotic agent to enable water to pass across the peritoneum. Some patients 
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lose the osmotic effect of glucose quickly, but large icodextrin molecules, which are not 
easily transported across the peritoneal membrane, maintain an osmotic gradient. Icodextrin 
is not metabolised in the peritoneal cavity, but the polymer can move into the blood stream 
via the lymphatic system. During systemic circulation, icodextrin is mainly metabolised into 
maltose which accumulates due to a lack of circulating maltase. It is the accumulation in the 
systemic circulation of these metabolites of icodextrin that may lead to the disparity 
between finger stick and formal blood glucose measurement. Maltose interferes with 
glucose assays that use glucose dehydrogenase with cofactor pyrroloquinolinequinone 
(PQQ-GDH) leading to falsely increased readings. 
Because of the oxygen insensitivity of PQQ-GDH however, there is much commercial 
interest in producing a mutant form of the enzyme that retains its non-reactivity to oxygen 
but improving its specificity with respect to D-glucose. Recently, Roche have reported the 
successful production of a mutant strain of PQQ-GDH which shows no cross-reactivity with 
maltose. [23]  
Finally, it is worth mentioning that PQQ containing proteins lend themselves to an 
interesting electrode configuration. Whilst flavoproteins such as glucose oxidase exchange 
electrons with an electrode surface via small molecular weight mediators such as ferrocene, 
ferricyanide etc, PQQ containing enzymes can exchange electrons via cytochrome b562. This 
cytochrome will exchange electrons directly with the electrode surface without the need for 
any mediator molecule. [24] Information on PQQ-GDH can be found on the EXPASY 
Proteomics server at: http://expasy.org/enzyme/1.1.5.2. 
A new enzyme on the market which has just recently become commercially available to the 
biosensor industry is the flavo-protein FAD-GDH [25] (Toyobo Develops FAD-GDH Enzyme, 
produced by Aspergillus for SMBG http://www.toyobo.co.jp/e/press/press31072009.htm). As 
its name suggests, the enzyme catalyses the oxidation of glucose but does not utilise 
dioxygen as a co-reactant. It can react with a number of artificial electron acceptors such as 
the ferricyanide anion and the ferricinium cation. The enzyme, which is isolated from 
Aspergillus terreus shows good thermal stability and high selectivity for glucose. Its absorption 
spectrum is typical of flavoproteins showing two distinctive peaks corresponding to the 
oxidised flavin cofactor at 465nm and 385 nm. In the presence of glucose the enzyme is 
bleached and these characteristic absorption bands disappear. [26] According to the data sheet 
from the manufacturer (Toyobo, Japan) the enzyme has a pH optimum of 7.0 and a KM for 
glucose of 67.6mM. The information on the EXPASY proteomics server relating to this 
enzyme is at: http://expasy.org/enzyme/1.1.99.10. 
This enzyme is currently used in a number of glucose test strips including the OneTouch 
Verio family of test strips produced and supplied by LifeScan. The design of the OneTouch 
Verio BG test strip is shown in Figure 7. The test strip incorporates gold and palladium 
electrodes which are orientated in a co-facial manner. The dimensions of the two electrodes 
are defined and controlled during the manufacturing process by a die-punch process. The 
electrodes are separated from each other by a thin plastic spacer that has a nominal 
thickness of 95 μm. The glucose-sensitive reagents, citraconate buffer salts, potassium 
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ferricyanide mediator and flavo-protein glucose dehydrogenase (FAD-GDH), are laid down 
on the ‘bottom’ palladium electrode. FAD-GDH enzyme was selected for its high substrate-
specificity and non-reactivity towards oxygen. The strip may be defined as a ‘side-fill strip’ 
because blood may be applied to the 400 nL sample chamber from either the left or the right 
side of the test strip (Figure 7). The levels of glucose in the sample are determined within 5 
seconds, the BG value being shown on the meter display in geographically appropriate units 
(mg/dl or mM). 
 
Figure 7. Architecture of the OneTouch Verio glucose test strip. The test strip incorporates gold and 
palladium electrodes that are orientated in a cofacial manner. The dimensions of the two electrodes are 
defined and controlled during the manufacturing process by a die-punch process. The electrodes are 
separated from each other by a thin plastic spacer that has a nominal thickness of 95 μm. The glucose-
sensitive reagents, citraconate buffer salts, potassium ferricyanide mediator, and flavoprotein glucose 
dehydrogenase, are laid down on the “bottom” palladium electrode. The user can apply blood to the 
test strip either from the right hand side or the left hand side. The glucose level is reported within 5 
seconds of the start of the test procedure. 
Manufacturing process controls and built-in signal processing compensation mechanisms 
eliminate the need for user calibration coding, thus reducing the potential for user error. The 
meter uses a novel multi-pulse signal and has an improved glucose-Hct-temperature-
antioxidant compensation algorithm for higher accuracy and precision over a wide range of 
blood samples. The OneTouch Verio BG test strip is designed to work with meters that are 
technically equivalent but have different user interfaces. Currently available meters include 
OneTouch Verio, OneTouch VerioPro, and OneTouch VerioIQ. The performance 
characteristics of the OneTouch VerioPro BGMS are summarized as follows: plasma 
equivalent calibration; 0.4 μl sample size; FAD-GDH enzyme; 20–600 mg/dl glucose range; 
20–60% Hct range; 10–90% humidity range (non-condensing); 6–44°C temperature range; 
and up to 3048 m altitude use. A summary of the dehydrogenase enzymes currently used in 
commercial enzyme electrodes is shown in Table 1. 
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Enzyme Reacts with O2? Reacts with maltose?  
PQQ-Glucose Dehydrogenase No 
Yes (Not Genetically Engineered 
variant [23] ) 
NAD-Glucose Dehydrogenase No No 
NAD--hydroxybutyrate 
dehydrogenase 
No No 
FAD-Glucose Dehydrogenase No No 
Table 1. Commonly used dehydrogenase enzymes for Commercial Self testing Biosensors 
Shown below are examples of commercially available test strips for home use which 
incorporate dehydrogenase based enzymes. 
 
a. The Roche Accu-Check Aviva test strip. This test strip uses PQQ-GDH as the enzyme of choice. 
http://www.roche.com/products/product-details.htm?type=product&id=2  
b. The Abbott Optium Xceed glucose test strip. This strip uses NAD-Glucose dehydrogenase in the sensing 
chemistry. http://www.abbott-diabetescare.com/AU/ProductDetail.aspx?product=57 
c. The Abbott Optium Xceed ketone test strip. This strip uses NAD+ linked β-hydroxybutyrate dehydrogenase. 
Because it uses the same mediator chemistry as B, and hence operates at the same potential, the two strips can be 
used in the same meter. http://www.abbott-diabetescare.com/AU/ProductDetail.aspx?product=57 
d. The LifeScan OneTouch Verio test strip. This strip incorporates FAD-GDH in the strip chemistry to measure 
glucose in whole blood. http://www.lifescan.co.uk/ourproducts/teststrips/onetouchveriopro 
(Photograph courtesy of Mr Christopher Leach, LifeScan Scotland Ltd., Inverness, UK). 
Figure 8. Examples of commercially available test strips for self-testing utilising dehydrogenases.  
9. Biosensors using dehydrogenase enzymes for continuous monitoring 
9.1. FAD-GDH biosensor for continuous glucose monitoring 
It has been well established that many of the diabetic complications leading to both chronic 
and acute health problems, such as adult blindness, end-stage renal disease, lower-limb 
amputations, and heart disease or stroke, can be reduced or even prevented through intensive 
 
Amperometric Glucose Sensors for Whole Blood Measurement Based on Dehydrogenase Enzymes 337 
blood glucose control. [27-29] Effective glycaemic control requires frequent measurements of 
blood glucose in order to take necessary therapeutic interventions. Such an approach is 
exemplified by the use of so-called ‘continuous glucose monitoring’ (CGM) apparatus and 
methodologies that are used by a growing number of patients to monitor their diabetes 
condition. Such systems are composed of a probe that is inserted into the body such that it 
contacts glucose containing liquids in the body, such as interstitial fluid. These CGM 
systems are designed to operate over extended periods of time, typically over a number of 
days or longer. In reality CGM is a misnomer, inasmuch as the device samples in an 
episodic manner, but on a sufficiently high frequency to distinguish such devices from 
single measurement episodic systems. Nevertheless, compared with episodic self-
monitoring blood glucose (SMBG), CGM follows blood glucose dynamics and hence, 
provides patients and healthcare professionals with not only current blood glucose levels, 
but also real-time rate and direction of changes. Blood glucose thresholds can be set to alert 
for possible dangerous trends, for instance rapid blood glucose descents that may lead to 
hypoglycemia. Advances in CGM research and development are also critical to realize 
“artificial pancreas” of a closed-loop system in conjunction with an insulin pump.  
Enzyme catalysed electrochemical biosensors have been the most successful technology for 
the commercialized SMBG products (as discussed in the preceding part of this chapter). For 
CGM, enzymes are also employed as the means of target analyte recognition, coupled to 
electrochemical transduction methods for determination of the analyte of interest. 
Correspondingly, such systems have been so far limited to the use of a redox enzyme, such 
as glucose oxidase (GOx) in which the prosthetic group is intimately associated with the 
enzyme, such that it cannot diffuse or leach away over the duration of sensor operation.[30] 
Recently commercialized flavin adenine dinucleotide-dependent glucose dehydrogenase 
(FAD-GDH, EC 1.1.99.10), where the FAD moiety forms an integral part of the enzyme, has 
attracted great attention for blood glucose monitoring because of its advantages over GOx in 
terms of insensitivity to molecular oxygen. However, like many redox enzymes, direct 
electron transfer between FAD-GDH and electrode surface cannot occur because the active 
centre FAD is insulated by the large proteins. Therefore, mediators are usually employed to 
shuttle electron between the FAD moiety and electrode surface. An example of such 
mediators is potassium ferricyanide used for LifeScan OneTouch Verio family of SMBG 
products. However, use of small molecular mediators in biosensors faces tremendous 
technical challenges for CGM which requires essentially all the reactive reagents 
immobilized without leaching out from the electrodes to achieve long-term measurement 
stability and to meet biocompatibility requirements, in particular for in-vivo applications. 
An attractive approach to tackle this challenge is to use a polymeric mediator which has 
mediator moieties chemically attached to polymer chains. Because of its large molecular 
size, the polymeric mediator can be co-immobilized with enzyme at electrode by various 
means, including surface grafting, [31-34] layer-by-layer surface adsorption, [35-37] retention 
behind semi-permeable dialysis membranes,[38-40] physical entrapment [41-43] or cross-link in 
hydrogels, [44-47] entrapment in electropolymerized [48,49] or chemically formed layers [50] or in 
inorganic layers,[51,52] and blend in carbon pastes. [53]  
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At LifeScan Scotland Limited, we have synthesized a ferrocene polymeric mediator which is 
a copolymer of vinylferrocene, acrylamide and 2-(diethylamino)ethyl methacrylate.[54] Like 
small molecular mediators, an effective polymeric mediator for biosensors should be able to 
exchange electrons with enzyme prosthetic group and then be re-oxidized/re-reduced at 
electrode in a reversible manor at a sufficient low potential to avoid or minimize 
interferences resulting from oxidation/reduction of other components in the sample fluid, 
such as uric acid, ascorbic acid etc. in a bodily fluid. Figure 9 shows cyclic voltammograms 
of the ferrocene polymeric mediator and FAD-GDH (from Toyobo Co. Ltd., Japan) in 
phosphate buffered saline (PBS). In the absence of glucose, cyclic voltammetry shows almost 
symmetric anodic and cathodic peaks which are attributed to oxidation and reduction of the 
ferrocene moieties of the polymeric mediator. After adding 2.5 mM glucose, the cyclic 
voltammogram changed dramatically, with a large increase in the anodic peak and a 
significant decrease in the cathodic peak. This was a typical phenomenon of enzyme-
dependent catalytic reduction of ferrocenium generated during the oxidation half-cycle in 
the presence of glucose. The cathodic peak increased further as glucose concentration 
increased to 5.0 mM. These results clearly indicated that the ferrocene polymeric mediator 
exhibited preferential redox properties with respect to transfer of electrons from the reduced 
enzyme prosthetic group FADH2 to the glassy carbon electrode surface. The ferrocene 
moieties are reduced to ferrocenium moieties upon accepting the electrons from FADH2 and 
then are re-oxidized on transfer of electrons to the electrode.  
 
Figure 9. Cyclic voltammograms: 1.5mg/mL FAD-GDH, 9 mg/mL ferrocene polymeric mediator in 
0.01M pH7.4 PBS, scan rate 5 mV/s, without (solid line), with 2.5 mM glucose (broken line) & 5.0 mM 
glucose (dotted line) 
We have also developed a technique for co-immobilization of FAD-GDH and the ferrocene 
polymeric mediator in modified electrodes which were fabricated by screen-printing a water-
based carbon ink containing both the enzyme and the ferrocene polymeric mediator. The ink 
contained graphite particles as conductive pigments and a pH sensitive copolymer as a binder. 
[55] The copolymer binder was water-soluble in the presence of ammonium hydroxide and 
hence, the ink was miscible with dissolved FAD-GDH and the ferrocene polymeric mediator 
during the ink formulation. As ammonia evaporated upon drying a screen-printed ink pad, the 
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binder copolymer became water-insoluble and the ink layer evolved to form a 3-dimensional 
nano-porous structure which effectively entraps the large molecules of the enzyme and the 
ferrocene polymeric mediator whilst allows free diffusion of glucose and water molecules. [54] 
Figure 10 shows scanning electron microscopy image of the electrode surface.  
 
Figure 10. Scanning electrode microscopy image of an electrode with immobilized FAD-GDH and the 
ferrocene polymeric mediator 
The main advantages of these electrodes are 
 The enzyme and ferrocene polymeric mediator are co-immobilized in vicinity of the 
electrode graphite particles, which is beneficial for fast electron transfer.  
 The 3-dimensional nano-porous structure enables higher loading of the redox species 
and provides larger electrode surface area than a planar electrode with an enzyme layer.  
 No chemical reactions are involved throughout the immobilization and hence, potential 
enzyme denaturing is avoided.  
 The screen-printing technique suits mass production and has low manufacturing cost.  
Because of the presence of ammonium hydroxide, the water-based carbon ink was basic in 
nature. FAD-GDH stability in the wet ink was studied by comparing glucose sensitivity of 
the modified electrodes fabricated from the same batch of formulated ink with varied stand-
out time. The glucose sensitivity of the electrodes was assessed by testing current responses 
of a 3-electrode setup to glucose in a concentration range of 0 to 20 mM. The test conditions 
and results are presented in Figure 11. It is clearly seen that 2-day stand-out of the wet ink 
significantly reduced glucose calibration slope of the test. During the stand-out period, the 
wet ink containing FAD-GDH and the polymeric mediator was kept in a fridge at 4 C and 
negligible changes in ink rheology and solid content were detected. For comparison, the 
stand-out was also investigated for an ink using GOx as an enzyme and insignificant effect 
on glucose calibration slope was found. Therefore, the reduction in glucose sensitivity of the 
FAD-GDH working electrodes is attributed to decrease in the enzyme activity probably 
resulting from the enzyme denaturing in the basic wet ink.  
Since Clark and Lyons reported the first enzymatic electrode for glucose measurement in 
1962, [56] molecular oxygen has been involved in the enzymatic redox reactions as an electron 
acceptor for the first generation of biosensors. However, this type of biosensors is based on 
measuring generation of hydrogen peroxide or depletion of oxygen and hence, exhibits  
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Figure 11. Calibration plots for screen-printed electrodes prepared by using the ink printed after ink 
formulation without delay (☐) and the ink printed 2 days (■) after ink formulation, tested in 0.01M 
pH7.4 PBS by using an Ag/AgCl reference electrode and a platinum counter electrode, 0.3 V potential, 
room temperature, the error bars are first standard deviation of 7 electrodes 
fundamental limitations. Measurement of hydrogen peroxide requires relatively high 
operational potential (normally >0.45V) and suffers from significant interference resulting from 
oxidation of other substances in the bodily fluid. [57, 58] For oxygen measurement, the test result 
is sensitive to the variations in oxygen supply and test conditions. [59] The second generation 
biosensors use mediators to shuttle electrons between the enzyme prosthetic groups and 
electrodes. Typically, mediators have the attractive property of being selected for a particular 
desirable redox potential at which the mediators readily undergo redox reactions at the 
electrode whilst the redox reactions of the interferents are insignificant. However, for some 
enzymes, such as GOx, oxygen can compete with the mediators to accept electrons from the 
reduced prosthetic group FADH2 to form hydrogen peroxide which cannot be oxidized at the 
electrode under the applied potential for the mediator re-oxidation. As a result, the biosensor 
response to the analyte is dampened in the presence of oxygen. As shown in Figure 12, tested 
in PBS with a 3-electrode setup, the current response to 5 mM glucose for the screen-printed 
electrode modified with GOx and the ferrocene polymeric mediator decreased almost 60% as 
blood oxygen content increased from 8 Kpa to 23.14 Kpa. In contrast, the screen-printed 
electrode modified with FAD-GDH and the ferrocene polymeric mediator had little change in 
the current response in a range of the blood oxygen content from 9.8 Kpa to 20.1 Kpa.  
The oxygen insensitivity of FAD-GDH makes the enzyme very attractive for the development 
of CGM biosensors. This is because the biosensors using an oxygen-sensitive enzyme in 
general has more profound response dampening effect at low glucose concentrations due to 
the generation of hydrogen peroxide, which can contribute to significant accuracy error for the 
CGM and impose critical challenges for CGM to provide patients and healthcare professionals 
with a true picture of ambient glycemia profile which is critical for reliable detection and/or 
prediction of hypoglycemia, an important step to good diabetes management.  
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Figure 12. Effect of oxygen content on current response to 5 mM glucose in 0.01M pH7.4 PBS for 
screen-printed electrodes containing FAD-GHD (☐) and GOx (■), tested by using an Ag/AgCl reference 
electrode and a platinum counter electrode 
Like many medical devices, CGM biosensors normally need sterilization, in particular for in 
vivo or ex-vivo applications to eliminate any harmful contaminants such as fungi, bacteria, 
viruses, and spore forms etc. There are different established methods for sterilizing medical 
devices. Some of them involve the use of high energy means which can cause damages to 
materials in certain circumstances. It is essential that the key redox species, including FAD-
GDH and the ferrocene polymeric mediator in the biosensor are not subject to any significant 
damages during a chosen sterilization process. Figure 13 shows comparison of glucose 
calibration plots for the same batch electrodes fabricated by screen-printing the water-based 
carbon ink containing FAD-GDH and the ferrocene polymeric mediator before and after 25 
KGy e-beam sterilization. The results indicate 10-16% reduction in steady state current in the 
tested range of glucose concentrations. A sample of the ferrocene polymeric mediator also went 
through the sterilization process alongside the electrodes. 1H nuclear magnetic resonance and 
size exclusion chromatography indicated no change to the composition and molecular weight 
of the ferrocene polymeric mediator after the e-beam sterilization. The reduction in the current 
responses to glucose is probably attributed to e-beam induced decrease in the enzyme activity.  
 
Figure 13. Calibration plots for screen-printed electrodes before (☐) and after (■) 25 KGy e-beam 
sterilization, tested in 0.01M pH7.4 PBS by using an Ag/AgCl reference electrode and a platinum 
counter electrode, the error bars are first standard deviation of 7 electrodes 
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CGM biosensors were fabricated by sequentially screen-printing and drying a carbon ink, an 
Ag/AgCl ink and the water-based carbon ink containing FAD-GDH and the ferrocene 
polymeric mediator on the same plane of a plastic foil to form two carbon tracks, a pseudo-
reference electrode and a working electrode, respectively. Then the plastic foil was heat-
laminated onto a plastic disc which had pre-formed micro-channels (typical channel 
dimension: width x depth = 0.3 x 0.3 mm) in a way that the micro-channel runs over the two 
electrodes with the working electrode upstream of the pseudo-reference electrode. Surface 
areas exposed to the micro-channel are 0.3 x 2.0 mm and 0.3 x 5.5 mm for the working 
electrode and the pseudo-reference electrode, respectively. [54] For comparison, biosensors 
with GOx were also fabricated in the same way except for replacing FAD-GDH with GOx in 
the water-based carbon ink. Loadings of the two types of enzymes in the water-based 
carbon inks were identical in weight.  
The two types of biosensor discs were tested side-by-side at room temperature. Human 
blood samples were collected on the same day for the test. Upon testing, a continuous flow 
of the human blood samples were pumped from blood sample reservoirs through the 
channels of each biosensor at 15 μL per minute by using a peristaltic pump (Ismatec). Sensor 
current responses to blood glucose were recorded by using a potentiostat (Uniscan 
Instruments) operated at 0.3 V potential. Step changes of blood glucose concentration were 
realized by switching the blood sample reservoirs which were open to the atmosphere and 
under gentle magnetic agitation. Low glucose blood samples were prepared by standing the 
blood sample reservoirs in a 37 C water-bath to accelerate glucose consumption by blood 
cells, whilst high glucose blood samples were prepared by spiking with a 20% wt/wt glucose 
stock (from Sigma-Aldrich). YSI measurements (YSI 2300 STAT Glucose Analyzer) of 
glucose concentrations were performed for the blood samples as references. In order to 
minimize error caused by blood mixing in the disc channel upon changing glucose 
concentration, the YSI measurements were performed by taking a sample from the reservoir 
when the previous blood sample in the biosensor micro-channel was completely depleted 
indicated by steady sensor current. Given the slow decrease in blood glucose concentration 
with time at room temperature, two YSI measurements were normally performed for each 
blood sample during the period it flowed through the biosensor disc channel. 
In a typical test, the two types of biosensors were tested continuously over 54 hours with daily 
changes of blood samples from different donors. The disc channels were flushed with PBS 
(0.01 M, pH7.4) prior to the blood changes. Figure 14 shows typical recorded current responses 
of one FAD-GDH and one GOx biosensors to the same blood samples with varied glucose 
concentrations in a range of 2.29 to 25.64 mM between 23 and 30 hour test time. YSI measured 
blood glucose concentrations are also shown. For both biosensors, the currents clearly 
followed the step-changes in blood glucose concentration and reached “steady-state” in 3 to 5 
minutes. It is expected that the real response time of the biosensors to the blood glucose 
concentration changes is shorter than 3 to 5 minutes because the recorded steady-state currents 
can only be obtained after complete depletion of the “old” blood samples from the disc 
channels upon the reservoir switching. By a close look, the current response of the GOx 
biosensor clearly drifted whilst the current response of FAD-GDH sensor did not between 28.5 
 
Amperometric Glucose Sensors for Whole Blood Measurement Based on Dehydrogenase Enzymes 343 
and 30 hour test time. This is probably due to the oxygen effect on the GOx biosensor as 
oxygen content of the blood sample gradually increased under continuous agitation. 
The steady-state current responses of the two biosensors over the 54-hour test are plotted 
against the YSI measured blood glucose concentration in Figure 15. For both of the 
biosensors, the test results demonstrated good linear correlations between the current 
responses and blood glucose concentration over the tested glucose concentration range. 
However, the FAD-GDH biosensor had significantly higher current responses than the GOx 
biosensor, leading to higher sensitivity to glucose concentration variations and hence, 
potentially better measurement accuracy. This suggests that FAD-GDH has higher activity 
than GOx given that the enzyme loadings were the same for the two types of biosensors.  
 
Figure 14. Current response variations of sensors with screen-printed working electrodes containing 
FAD-GDH (solid line) and GOx (dotted line) and Ag/AgCl reference electrode, with varied blood 
glucose concentrations (), tested with continuous flow of human blood at a flow rate of 15 μL/min 
 
Figure 15. Calibration plots of sensors with screen-printed working electrodes containing FAD-GDH  
(□) and GOx (■) respectively and Ag/AgCl reference electrode, tested with continuous flow of human 
blood at a flow rate of 15 μL/min 
Because the blood cells continuously consumed glucose and result in gradual decrease in 
blood glucose concentration at room temperature, direct assessment on measurement 
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stability of the biosensors by recording sensor response change with time at a fixed glucose 
concentration proved to be unreliable. Nevertheless, closely aligned data points to the linear 
regression line in Figure 15 illustrate stable biosensor response during the 54-hour test, 
suggesting good FAD-GDH stability during the continuous measurement. 
9.2. NAD and ferrocene polymeric mediator redox couple  
As a coenzyme for hundreds of oxidoreductases, NAD has attracted great attention for 
biosensor development. Because its direct oxidation at electrode surface requires high 
applied potential and involves side reactions leading to the formation of electrochemically 
inactive by-products (see the preceding section), NAD is normally coupled with mediators 
for its application in biosensors. In the literature, ferrocenium and its derivatives have been 
reported as mediator for oxidation of NADH to NAD+. [60-63] As mentioned in the preceding 
section, small molecular mediators are not normally suitable for continuous monitoring 
biosensors. The effective immobilization of the ferrocene polymeric mediator in the screen-
printed carbon electrode developed at LifeScan Scotland Limited holds potentials for 
development of continuous monitoring biosensors using NAD-dependant oxidoreductases. 
To investigate electrochemical communication between NAD and the immobilized 
ferrocene polymeric mediator, 0.3 V potential (ECOChemie PGSTat Autolab, Type III) was 
applied to an electrochemical cell containing 3.0 mL 0.01M pH7.4 PBS and equipped with a 
screen-printed carbon electrode (approximately dimension length x width = 10 x 5 mm) with 
immobilized ferrocene polymeric mediator (about 12.5% wt/wt), an Ag/AgCl reference 
electrode and a platinum counter electrode to oxidize the ferrocene moieties of the 
polymeric mediator to ferrocenium moieties. After the current of ferrocene oxidation 
reached a steady level, PBS in the cell was replaced with 0.3 mM NADH (from Sigma-
Aldrich) in 3.0 mL 0.01M pH7.4 and a step increase in current was detected, which indicated 
oxidation of NADH by the ferrocenium moieties of the polymeric mediator. The NADH 
oxidation was followed by measuring absorbance of the solution at 340 nm wavelength by 
UV/vis spectroscopy (Cecil Instruments, CE9500) at different time intervals. The result 
shown in Figure 16 illustrates gradual decrease in NADH concentration (E340 = 6,330) with 
the oxidation time, which can be attributed to continuous oxidation of NADH by the 
ferrocene polymeric mediator immobilized in the carbon electrode. 
0.65 mL above oxidized NADH solution was collected and mixed with 0.25 mL 99.5% 
ethanol (EtOH, Sigma-Aldrich) in a UV cuvette (l = 1cm). UV spectra of the solution in the 
cuvette were recorded before and after addition of 0.4 mg alcohol dehydrogenase (ADH, 
Sigma-Aldrich). As shown in Figure 17, the addition of EtOH and ADH increased the 
absorbance peak at around 340 nm to almost the same level as the control solution which 
contained 0.3 mM NADH in 0.01M pH7.4 PBS and did not subject to the oxidation process. 
This suggests that NADH oxidation by the immobilized ferrocene polymeric mediator 
predominantly, if not completely produced electrochemically active NAD+ that was reduced 
to NADH by EtOH in the presence of ADH. 
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Figure 16. Variation of UV absorbance at 340 nm of 0.3 mM NADH in 0.01 M pH7.4 PBS by carbon 
electrode with immobilized ferrocene polymeric mediator at 0.3 V potential, by using an Ag/AgCl 
reference electrode and a platinum counter electrode, at room temperature  
 
Figure 17. UV spectroscopy monitoring reduction of oxidized NADH in the presence of ADH and 
EtOH, 0.65ml NADH (0.2 mM) + 0.25ml EtOH (99.5%) + 20ul ADH (control) (solid line), 0.65ml oxidized 
NADH + 0.15mL EtOH (before reduction) (broken line), 0.65ml oxidized NADH + 0.25ml EtOH + 20 ul 
ADH (4mg/ml) (dotted line) 
For continuous monitoring, use of native NAD as a coenzyme apparently is not ideal due to its 
low molecular weight and high water-solubility. Direct immobilization of free NAD at electrode 
has been a long-standing challenge. [64, 65] There are a large number of publications in the literature 
concerned with NAD retention for various purposes. In the field of biosensors, one promising 
approach is covalently attaching NAD moieties to polymer chains which can be immobilized at 
electrode by different means. This can be achieved by directly coupling NAD to an electrode 
modified with a polymer bearing functional groups,[66] entrapping polymeric NAD in semi-
permeable membranes [67, 68] or synthesizing a charged polymeric NAD which was then 
physically adsorbed at electrode surface in conjunction with counter-charged polymer(s) in a 
manner of layer-by-layer. [69] At LifeScan Scotland Limited, we intend to develop continuous 
monitoring biosensors using NAD-dependent enzymes by immobilizing all the redox species, i.e. 
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an enzyme(s), the ferrocene polymeric mediator and a polymeric NAD in an electrode with the 3-
dimentional nano-porous structure (see Figure 10). A polymeric NAD is normally synthesized by 
two routes. One is coupling NAD or NAD analogue with a polymer bearing functional groups. 
[66, 70-73] The other route involves synthesis of a NAD monomer and then its copolymerisation with 
another co-monomer(s). One of the challenges for NAD immobilization is to keep NAD 
coenzymic activity while achieving effective retention at electrode. Yamazaki et al synthesized 
three NAD monomers (N6-[N-(6-methacrylamidohexyl)carbamoylmethyl]-, N6[N-[2-[N-(2-
methacrylamidoethyl)carbamoyl]ethyl] carbamoylmethyl]-, and N6-[N-[N-(2-hydroxy-3-
methacrylamidopropyl) carbamoylmethyl] carbamoylmethyl]-NAD) and then copolymerized 
them with various co-monomers (acrylamide, N-(2-hydroxyethyl)-, N-ethyl-, N,N-diethyl-, and 
N,N-dimethylacrylamide, acrylic acid, and 6-methacrylamidohexylammonium) by free radical 
polymerisation to form a series of polymeric NADs. [74] Their studies revealed that hydrophilicity 
and length of the spacers linking NAD moieties and the polymer backbone had the most 
important effects on coenzymic activity of the polymeric NADs. This suggests that keeping 
mobility of the NAD moieties covalently attached to a polymer chain is critical to NAD 
coenzymic activity. Chemically modification to native NAD is required to tailor chemical 
properties of the spacers. N6-amino group on the adenine ring of NAD (see Figure 18) is 
normally selected as the site for this purpose. [75, 76] Lindberg et al reported alkylation of NAD+ 
with iodoacetic acid followed by alkaline rearrangement to give N6-carboxymethyl-NAD+.[75] 
However, the reaction between NAD+ and iodoacetic acid took 10 days in the dark at room 
temperature. We successfully synthesized N6-carboxymethyl-NAD+ by a modified method with 
a dramatic reduction in the reaction time.  
 
Figure 18. Chemical structure of NAD+ 
9.4. Synthesis of N1-carboxymethyl-NAD+ (compound 1 in Figure 19) 
1.0g NAD+ (1.51mmol) was dissolved in 3.5mL 0.1M pH 7.0 sodium phosphate buffer in a 5ml 
Biotage microwave reaction tube. Then, 1.5 g (8.06mmol, 5.34eq) iodoacetic acid was added 
and pH was adjusted to 7.0 by using 5.0M NaOH aqueous solution. The reaction vessel was 
sealed and the mixture was heated to 50°C for 10 minutes by using microwave irradiation. 
After that, the pink solution (c.a. 5.0 mL) was acidified to pH3.0 using 5M HCl aqueous 
solution before being poured into 25 mL pre-cooled (-5°C) mixture of acetone/IMS (1:1). The 
resulting precipitate was filtered, washed first with 5.0 mL IMS, then 15 mL dry diethyl ether 
before air drying under dry nitrogen for 10 minutes. Further drying overnight in a desiccator 
over fused CaCl2 gave 1.62 g crude N1-carboxymethyl-NAD+ as a pink amorphous solid.  
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9.5. Synthesis of N6-carboxymethyl-NADH (compound 2 in Figure 19) 
9.1g (c.a. 10.57mmol) above prepared crude N1-carboxymethyl-NAD+ was dissolved in 
1.3% w/v NaHCO3 in 450 mL aqueous solution and the solution was deoxygenated by 
sparging with nitrogen for 10 minutes. 3.5 g (20.1mmol) sodium dithionite was added in 
one portion and the mixture was stirred at ambient temperature to affect reduction of the 
nicotinamide moiety. After 1.0 hour, the solution colour changed from pink to yellow. The 
solution was then sparged with air for 10 minutes to destroy any excess dithionite and the 
pH was brought to 11.0 by using 5M NaOH aqueous solution. The mixture was heated at 
70°C for 90 minutes, to promote Dimroth rearrangement to N6-carboxymethyl-NADH, 
before cooling to 25°C. Thin-layer chromatography (silica gel, isobutryic acid/water/32% 
NH4OH (aq), 66/33/1.5 by volume) showed no evidence for the presence of N1-
carboxymethyl-NADH. 
9.6. Oxidation of N6-carboxymethyl-NADH to N6-carboxymethyl-NAD+ 
(compound 3 in Figure 19) 
The reaction mixture containing N6-carboxymethyl-NADH was treated with 17.5 mL 3M 
Tris buffer (pH7.0) and the pH was adjusted to 7.5 using 5M HCl aqueous solution. 3.5 mL 
acetaldehyde (62.6mmol) was added, immediately followed by 10.5 mg yeast alcohol 
dehydrogenase (saccharomyces cerevisiae) (~300U/mg) before allowing agitating at ambient 
temperature to deoxidize the nicotinamide moiety. After 18 hours, the reaction mixture (c.a. 
485 mL) was concentrated in vacuo (30°C/10-15bar) to approximately 1/3 volume and poured 
into 1800 mL pre-cooled (-5°C) mixture of acetone/IMS (1:1). The fine slurry was left to age 
for 18 hours at 3°C. The resulting precipitate was collected by centrifugation and washed on 
a glass sinter with 40 mL IMS then 120 mL dry diethyl ether before air-drying under dry 
nitrogen for 10 minutes. Further drying overnight in a desiccator over fused CaCl2 afforded 
3.99g crude N6-carboxymethyl-NAD+ as a tan coloured hygroscopic solid.  
1.0 g of the above-prepared crude N6-carboxymethyl-NAD+ was taken up in 20 mL water 
and passed through a Sephadex G10 gel filtration column (2x10cm, 20 mL). All eluted 
fractions containing UV active material were combined (60 mL total volume) and added to a 
column of Dowex 1-X2 ion exchange resin (Cl-, 4x50cm, 200 mL) which had been pre-
equilibrated with water. A linear gradient of 0-50 mM LiCl (buffered to pH 3.0), at 10 mL 
per minute over 65 minutes, was applied using “Presearch Combiflash Companion” 
chromatography equipment. The fractions eluted between 25-35 mM were combined (c.a. 
100 mL), neutralized to pH 7.0 with 5M LiOH and evaporated to approximately 1/3 volume 
and poured into 300 mL pre-cooled (-5°C) mixture of acetone/IMS (1:1). The fine slurry was 
left to age for 18 hours at 3°C. The resulting precipitate was collected by centrifugation and 
washed on a glass sinter with 30 mL IMS then 50 mL dry diethyl ether before air-drying 
under dry nitrogen for 10 minutes. Further drying overnight in a desiccator over fused 
CaCl2 afforded 0.307g purified N6-carboxymethyl-NAD+ as a cream coloured hygroscopic 
solid.  
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Figure 19. Synthesis of N6-carboxymethyl-NAD+ 
The synthesized N6-carboxymethyl-NAD+ is an important intermediate for NAD 
immobilization at electrodes for continuous monitoring biosensors. An extension of this 
work could involve synthesis of various polymeric NADs with tailor-made chemical 
properties to meet biosensor requirements for continuous monitoring of different analytes. 
10. Conclusions 
In this article we have outlined various strategies for the electrochemical exploitation of 
dehydrogenase enzymes in sensor devices. The techniques used ultimately depend upon the 
class of dehydrogenase enzyme used. For enzymes that are NAD(P)+ linked it is essential to 
develop a base transducer (a modified electrode) that efficiently reoxidises the reduced 
coenzyme. Alternatively, sensing schemes can be designed which utilize Diaphorase thereby 
facilitating the biochemical oxidation of reduced coenzyme. With FAD and PQQ dependent 
enzymes the most successful strategy has been to utilize mediator molecules such as the 
ferricyanide anion to couple the enzymatic activity to the electrode. Although not yet 
exploited commercially, dehydrogenase enzymes could also have a role in continuous 
monitors. With the NAD+ dependent enzymes there is the additional complication of 
immobilizing the chemical components of the sensor to prevent drift in the device over time. 
This also includes the coenzyme molecule and we have illustrated how the synthesis of the 
N6-carboxymethyl derivative of NAD can be an important intermediate in achieving this. 
Attachment of suitable ligands at this position, with sufficient flexibility, should allow the 
development of stable reagents which will facilitate the development of continuous devices. 
The electrochemistry of NADH oxidation has been well researched over the last 30 years. 
Also, over 250 enzymes use this ubiquitous coenzyme so schemes which utilize NAD 
dependent enzymes should allow for the measurement of a range of analytes in blood. In 
spite of this, it is interesting to note that with the exception of Abbott, none of the other 
major biosensor manufacturers have embraced this technology. The reason for this could be 
due to the fact that glucose SMBG is still the largest biosensor market worldwide and it is 
adequately served by enzymes such as glucose oxidase, FAD-GDH and PQQ-GDH, none of 
N
+
NH2
O
OH
H
H
OH
H
H
O
OH
H
H
OH
H
H
O
O
P
O
P
O
OH
O
OH
O
.
NH2
O
N
H H
OH
H
H
OH
H
H
O
OH
H
H
OH
H
H
O
O
P
O
P
O
OH
O
OH
O
.
R-ox: R-red:
N
N
N
N
NH2
R-ox
N
N
+ N
N
NH2
R-ox
C
OH
O
iodoacetic 
acid
N
N
+ N
N
NH2
R-red
C
OH
O
rearrangment
N
N
N
N
NH
R-ox
C OH
O
enzyme 
reduction
1 2 3
 
Amperometric Glucose Sensors for Whole Blood Measurement Based on Dehydrogenase Enzymes 349 
which require any exogenous coenzyme to function. This makes the manufacture of the 
sensor relatively straight forward compared to those that require a modified electrode, an 
enzyme and in addition exogenous coenzyme added to the enzyme ink. In addition, 
switching to a NAD-dehydrogenase system may be incompatible with the manufacturing 
equipment currently used by manufacturers and thus prevent the adoption of this 
technology.  
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